Short answer: AI visibility in medical devices and health technology depends on two questions: is the brand in the answer, and is it represented accurately? In a regulated sector, a wrong indication, an old model or an outdated certificate can carry more risk than not appearing at all. AI visibility for medical devices is built on verifiable regulatory information and a single, consistent product source.
The biomedical engineer at a 600-bed private hospital in Anatolia is researching new bedside monitors for intensive care. Procurement expects three quotes. The engineer asks AI first:
Decision question · Biomedical engineer
“Which ICU bedside monitor brands are registered in Turkey’s national product tracking system (ÜTS), support HL7 integration with the hospital information system and have local technical service?”
The answer names four brands. One of them is problematic in how it’s described: the model describes the brand’s model from two generations ago and gives service network details for a product that is no longer manufactured. A local manufacturer whose current model meets every condition isn’t on the list at all.
The scenario is fictional. The sector faces two risks at once: not appearing, and appearing wrongly.
Why does accuracy come before visibility in a regulated sector?
In general B2B markets, a brand appearing with incomplete or outdated information is usually a lost opportunity. In healthcare, the consequences can be different. A wrong indication, a recalled product, an expired certificate or an off-label use suggestion can steer a purchasing decision the wrong way and expose the brand to compliance questions.
That’s why Recro measures healthcare on two axes: is the brand in the answer, and is what the answer says correct? The second axis, often secondary in other sectors, matters at least as much as the first here.
Who asks what in a hospital?
| Persona | Typical decision question | Evidence sought |
|---|---|---|
| Biomedical engineer | “… brands registered in ÜTS with local service” | Regulatory registration, technical specs, service network, spare parts |
| Clinician / department lead | “Which devices for … have strong clinical evidence?” | Clinical studies, publications, guideline references |
| Procurement | “Options with reimbursement codes and low total cost of ownership” | Reimbursement status, consumable costs, warranty |
| IT | “Health software that integrates with the HIS and complies with data protection law” | Integration standards, data residency, security |
In a hospital, the purchasing decision requires the joint approval of these four personas. A brand can be represented accurately in one persona’s question and incompletely in another’s.
Which sources does the model use to verify a medical product?
Healthcare has a clearer evidence hierarchy than other sectors, and the model largely follows it:
- Regulatory records: CE marking and risk class, notified body information, ÜTS registration in Turkey, EUDAMED records in the EU.
- Clinical evidence: Peer-reviewed publications, clinical studies, congress presentations.
- Reimbursement and public sources: Reimbursement coverage and records of public procurement.
- Manufacturer sources: Product pages, instructions for use, technical specification tables.
The manufacturer’s site sits at the bottom of this hierarchy. But if it doesn’t clearly provide the core information the model will match with other sources (product name, model, indication, risk class, registration numbers), the match fails and the model turns to old or third-party information.
How does misrepresentation happen, and how is it reduced?
The most common causes we see in the field are three. First, product names used inconsistently across generations: the same product family appears under different names in different sources. Second, old product pages being removed or not updated: the model keeps finding old information elsewhere but can’t find the current status. Third, outdated content on distributor websites.
The effective fix is a “single source of truth” approach. For each product, state the current model, indication, risk class, registration details and production status clearly on one page. For discontinued products, keep a page stating the status and the current successor instead of deleting it. Share the same product names and technical information with distributors. In Recro’s classification, these inconsistencies count as both a Content GAP and an Authority GAP.
How do promotion rules set the boundaries for content?
In Turkey, the sale, advertising and promotion of medical devices is governed by dedicated regulation, and promotion to the general public is heavily restricted. Similar rules apply in the EU and other markets. Content in healthcare must therefore be informative, verifiable and limited to the scope of the product’s authorization. Off-label use, unproven superiority claims and patient-directed language fall outside that scope. Content should be reviewed by regulatory and compliance teams before publication.
This boundary doesn’t hinder visibility. The signal the model looks for is regulatory information, technical data and clinical evidence. Marketing language rarely carries into the model’s answers in this sector.
How does the question change for health software?
For health technologies such as hospital information systems, imaging software and remote monitoring platforms, the IT team’s questions lead: integration standards such as HL7 and FHIR, compatibility with the existing HIS, processing health data as special category personal data under data protection law, and where data is stored. Whether the software is classified as a medical device also comes up often in verification questions.
Companies that share this information only at the proposal stage don’t appear in the IT team’s discovery question. The dynamic resembles the alternative question in B2B SaaS: in risk-driven questions, the product with clear evidence comes forward.
How does Recro make this gap visible?
The Recro Insight Model measures visibility and accuracy together in healthcare. Beyond whether the brand appears, what the answer says about it is checked. Non-appearance and misrepresentation are classified separately; corrective actions are recommended within regulatory limits.
One simulation · 4 key pillars · 90+ steps
What sets Recro apart is four pillars built from scratch for each brand. Together they form a single simulation of 90+ steps, with each pillar producing the input for the next.
- Persona builder: Decision-maker profiles that represent the brand’s real buyers, specific to its sector and sales structure.
- Question builder: The brand-specific decision questions these people ask AI along their buying journey.
- Report builder: A report that reads the answers against the brand’s goals and competitors, together with the sources behind them.
- Action recommendation builder: A prioritized list of actions that closes the sector-specific signal gaps.
Sample finding format · illustrative
- Question: Verification · Biomedical engineer · “What are the features of [Brand] monitors?”
- Status: The model presents a discontinued model’s features as the current product.
- Reason: The old product page was removed; a distributor site still carries the old information.
- Class: Misrepresentation · Content GAP + Authority GAP
- Action: Status page for the old model, link to the current product, updated distributor content.
Executive summary
- In healthcare, measurement has two axes: is the brand in the answer, and is it described correctly? Misrepresentation can carry more risk than invisibility.
- The model verifies products through regulatory records and clinical evidence. The manufacturer’s site must clearly provide the core information that matches these sources.
- A single source of truth reduces misrepresentation caused by old products and distributor content.
Frequently asked questions
Can we produce content for AI visibility given promotion restrictions?
Informative, verifiable content can be produced: product descriptions, technical specifications, regulatory information, references to clinical publications. All content should pass regulatory and compliance review.
What can we do if AI gives wrong information about our product?
The model can’t be corrected directly. What can be done is to strengthen the sources where correct information is published clearly and consistently, and to update the source of the wrong information (old page, distributor content). The effect shows over different timeframes depending on the tool and source type.
Should we delete pages for discontinued products?
Keeping a page that states the status is usually safer: production status, how long service and spare parts support will last, the current successor. That way the model finds the old information together with the current status.
Does information on distributor websites affect us?
Yes. Distributor sites are among the external sources the model uses. Keeping product names and technical information shared and current with distributors closes a major source of misrepresentation.
Does the same approach apply in international markets?
The structure is the same; sources and language differ. In the EU market, EUDAMED and MDR scope, English and local-language content come forward. We cover the language difference in why brand visibility differs between Turkish and English prompts.
When a biomedical engineer asks AI about your product tomorrow, will the answer have the right model, the right indication and the right registration details? Recro simulates visibility and accuracy together in healthcare.
Request a healthcare simulation →
This article was prepared with AI assistance and published under the review of Mehmet Semih İpek.
